Literature DB >> 19462463

Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.

Zhigang Zhao1, Jieming Liu, Su Li, Wenlu Shen.   

Abstract

BACKGROUND: Recent data showed that prostate stem cell antigen (PSCA) mRNA expression in transurethral resection of the prostate (TURP)-resected tissues predicted the subsequent prostate cancer after TURP in benign prostatic hyperplasia (BPH) patients with both PSA < 4.0 ng/ml and normal DRE findings. This study was to determine whether PSCA mRNA positivity in preoperatively negative prostatic biopsy samples from BPH men with PSA > 4.0 ng/ml and/or suspicious DRE findings had predictive performance following TURP.
MATERIALS AND METHODS: PSCA in situ hybridization was performed on negative prostatic biopsies taken before TURP from 166 enrolled symptomatic BPH patients, who were continuously followed for 5 years postoperatively. Predictive performance of PSCA mRNA for subsequent cancer onset was evaluated by univariate and multivariate Cox proportional hazards models with bootstrapping and concordance indices.
RESULTS: PSCA mRNA was detected in 42/166 (25.3%) of the preoperatively negative biopsy specimens, with a mean positive-labeling cells of 31.6%, in which 31 patients were identified as having subsequent PCa on follow-up. Of 124 patients with negative expression for PSCA mRNA none were subsequently diagnosed with PCa. The examination of Spearman's rank correlation coefficient showed that PSCA mRNA expression levels were positively and statistically correlated with higher Gleason score (r = 0.88, P < 0.001) and clinical T stage (r = 0.84, P < 0.001). A final multivariate Cox proportional hazards model demonstrated that only PSCA mRNA expression in negative prostatic biopsies was predictive of the subsequent cancer development after TURP (hazard ratio = 3.49; 95% CI: 2.02-4.75; P < 0.001), with the concordance index of 0.893.
CONCLUSIONS: This prospective study identifies PSCA mRNA in preoperatively negative prostatic biopsies as a significant predictor of subsequent cancer after TURP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19462463     DOI: 10.1002/pros.20973

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

Review 1.  Prostate stem cell antigen: a Jekyll and Hyde molecule?

Authors:  Norihisa Saeki; Jian Gu; Teruhiko Yoshida; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.

Authors:  Mohamed S Fawzy; Randa H Mohamed; Abdel-Rahman R Elfayoumi
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

Review 3.  Emerging biomarkers of prostate cancer (Review).

Authors:  Sarah K Martin; Taylor B Vaughan; Timothy Atkinson; Haining Zhu; Natasha Kyprianou
Journal:  Oncol Rep       Date:  2012-05-25       Impact factor: 3.906

4.  Lack of association between the rs2294008 polymorphism in the prostate stem cell antigen gene and colorectal neoplasia: a case-control and immunohistochemical study.

Authors:  Christopher Smith; Paul Lochhead; Umesh Basavaraju; Georgina L Hold; Nicky Fyfe; Graeme I Murray; Emad M El-Omar
Journal:  BMC Res Notes       Date:  2012-07-23

5.  Markers of field cancerization: proposed clinical applications in prostate biopsies.

Authors:  Kristina A Trujillo; Anna C Jones; Jeffrey K Griffith; Marco Bisoffi
Journal:  Prostate Cancer       Date:  2012-05-14

6.  MRl of prostate cancer antigen expression for diagnosis and immunotherapy.

Authors:  Jing Ren; Fang Wang; Guangquan Wei; Yong Yang; Ying Liu; Mengqi Wei; Yi Huan; Andrew C Larson; Zhuoli Zhang
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.